Thursday, September 20, 2012

Drug update- A Complete update on Drugs for health care professionals..


Drug update- A  Complete  update on Drugs for Doctors..
by-Shamna M,Sr lecturer

NEW DRUG APPROVALS
Aflibercept - August 3, 2012 — Aflibercept,an angiogenesis inhibitor(Anti VEGF) has been approved by the US Food and Drug Administration (FDA) for use in the treatment of metastatic colorectal cancer. The indication is for use in combination with the conventional FOLFIRI regimen (leucovorin, irinotecan, 5-fluorouracil).
Enzalutamide - August 31, 2012 — Enzalutamide, an anti androgen has been approved by US Food and Drug Administration (FDA) to treat men with metastatic castration-resistant prostate cancer that has spread or recurred.
FingolimodFingolimod, sphingosine-1-phosphate receptor modulator is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). Recommended dose is 0.5md once daily, with/without food.
Linaclotide -  August 30, 2012 – Linaclotide, guanylate cyclase type C agonist (GCC agonist) has been approved by US Food and Drug Administration (FDA) for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) in adults.
Pertzumab – Pertuzumab, a humanized monoclonal antibody, which inhibits HER 2 (Human epidermal growth factor receptor) has been approved by US Food and Drug Administration (FDA) for the treatment of HER 2 positive breast cancer.
Phentermine-topiramate combo- July 17, 2012, a controlled-release preparation of phentermine and topiramate in one capsule, is now indicated for use in adults with a body mass index (BMI) >30 kg/m2.
Glucarpidase - January 17, 2012 — Glucarpidase, a recombinant enzyme, has been approved approved as a treatment for the rapid and sustained reduction of toxic methotrexate levels due to impaired renal function.
Mirabegron - June 28, 2012- Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Everolimus - An mTOR (mammalian target of rapamycin) has been approved for the treatment of breast cancer in females.
Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)  
Aug. 28, 2012 -- Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) has been approved by the U.S. Food and Drug Administration to treat adults with HIV, the virus that causes AIDS. The combination drug, which only has to be taken once a day interferes with enzymes that are needed for the virus to multiply.
tbo-filgrastim
August 29, 2012 -- The U.S. Food and Drug Administration approved tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils. It is intended for use in adults who have cancers other than blood or bone marrow cancers (non-myeloid malignancies) and are taking chemotherapy drugs that cause a substantial decrease in the production of neutrophils in the bone marrow. This reduction in neutrophils may lead to infection and fever (febrile neutropenia). It stimulates the bone marrow to increase the production of neutrophils. It is administered as an injection beginning 24 hours after chemotherapy treatment.
FDA Approves Vaccines for the 2012-2013 Influenza Season
August 13, 2012 - Each year experts from the FDA, the World Health Organization, the Centers for Disease Control and Prevention (CDC), and other public health experts study influenza virus samples and global disease patterns to identify virus strains likely to cause the most illness during the upcoming flu season. Based on that information and the recommendations of the FDA’s Vaccines and Related Biological Products Advisory Committee, the strains selected for inclusion in the 2012-2013 flu vaccines are:
·         A/California/7/2009 (H1N1)-like virus
·         A/Victoria/361/2011 (H3N2)-like virus
·         B/Wisconsin/1/2010-like virus.
While the H1N1 virus is the same as what was included in the 2011-2012 influenza vaccines, this year’s influenza H3N2 and B viruses differ from those in the 2011-2012 influenza vaccines.

Qsymia (Phentermine and Topiramate extended-release)
FDAapproved Qsymia (Phentermine and Topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management. The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).
NEW DOSAGE FORM FOR EXISTING DRUGS
Afinitor Disperz - First Drug Formulated for Children with Rare Brain Tumor
August 29, 2012 -- The U.S. Food and Drug Administration approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma (SEGA). Afinitor Disperz is the first approved pediatric-specific dosage form developed for the treatment of a pediatric tumor. It is recommended to treat patients ages 1 year and older with tuberous sclerosis complex (TSC) who are diagnosed with SEGA that cannot be treated with surgery. Prior to approval of this new dosage form, Afinitor was recommended for use only in patients ages 3 years old and older. Afinitor was granted accelerated approval in 2010 to treat SEGA in patients with TSC.
FDA Approves Nucynta ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Aug. 29, 2012 -- U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Nucynta ER (tapentadol) extended-release tablets, an oral analgesic taken twice daily, for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. It is the first and only opioid approved by the FDA for neuropathic pain associated with DPN. In addition to this new indication, Nucynta ER is currently approved for the management of moderate to severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time

NEW INDICATION FOR EXISTING DRUGS
                Linagliptin - FDA approves updated prescribing information for Linagliptin tablets for add-on therapy to insulin in adults with type 2 diabetes.
Gabapentin enacarbil - The US Food and Drug Administration (FDA) has approved gabapentin enacarbil extended-release tablets for the management of post herpetic neuralgia in adults.

                FDA Approves Auvi-Q (Epinephrine injection, USP) - Aug. 13, 2012 -- FDA has approved Auvi-Q (Epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Auvi-Q is the first-and-only compact epinephrine auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.

GENERIC APPROVALS
FDA Approves Generic Versions of Actos
Aug. 17, 2012 -- The first generic versions of Pioglitazone (Actos) have been approved by the U.S. Food and Drug Administration to help adults with type 2 diabetes control blood glucose levels. License to produce the generic versions in 15 milligrams (mg), 30 mg and 45 mg strengths was granted to Mylan Pharmaceuticals. As with the brand name drug, generic versions will contain a label warning that the drug could cause or worsen heart failure in certain people. And there may be an increased risk of bladder cancer in people who take the drug for more than a year.
NEW DEVELOPMENTS IN MEDICARE FIELD
FDA Approves Digestible Microchips to be Placed in Pills
August 3, 2012 — The US Food and Drug Administration (FDA) has approved the first ingestible sensor. The Ingestion Event Marker (IEM), by Proteus Health, represents a new category of medical device: It is made entirely of ingredients found in food and is activated on ingestion.
The FDA validation represents a major milestone in digital medicine. Directly digitizing pills, for the first time, in conjunction with wireless infrastructure, may prove to be the new standard for influencing medication adherence and significantly aid chronic disease management.
The sensor resembles a grain of sand in size, is made primarily of silicon, and can be integrated into an inert pill or any other ingestible object (such as a pharmaceutical). The Proteus Digital Health feedback system integrates wearable and ingestible sensor technologies to detect medication intake and physiologic data.
A disposable patch is worn on the body to capture and relay the body's physiological response and behaviors. In addition to recording information from the sensor, the patch records heart rate, temperature, activity, and rest patterns. The patch lasts approximately 7 days and is operated by a battery, which also lasts approximately 7 days.
A mobile device is then carried in the pocket or purse to display data in context and support care.
The sensor can be used to detect the exact time medication is taken, as well as the unique identity of the medication. The information is controlled by the patient.
The IEM does not contain a battery. Instead, the fluids in the stomach power the sensor, and the body transmits the digital signal generated by the sensor. The IEM is the only ingestible sensor that is powered by the body. The sensor passes through the body similar to fiber.
Vascular Endothelial Growth Factor Inhibitors (Anti-VEGF) in the Management of Diabetic Macular Oedema
As an alternative treatment for DMO, anti-vascular endothelial growth factors (anti-VEGF) have been introduced. Different types of anti-VEGF are available, all of which inhibit VEGF angiogenic activity by binding to the VEGF protein and thus preventing its receptor activation.
Pegaptanib (PG) is a pegylated aptamer that targets only the VEGF 165 isoform and is currently approved for the treatment of neovascular age-related macular degeneration (AMD). Bevacizumab (IVB) is a full-length humanised antibody that binds to all types of VEGF. It is used in and licensed for tumour therapy. Ranibizumab (RBZ), it is a humanised monoclonal antibody fragment that binds all active forms of VEGF-A and is currently approved for AMD and DMO.
In summary, only RBZ has been approved for the treatment of DMO in Europe. RBZ and IVB were both developed by Genentech (now part of Roche), but Roche-Genentech has not sought a licence for the use of IVB in the eye. However, due to the very high price of RBZ, IVB has regularly been used off label while experimental studies are underway. The therapeutic aim of anti-VEGF injections in patients with DMO is to improve and stabilise quality of vision and, ultimately, to improve quality of life which is severely threatened by visual loss (eg, increased risk of falls, severe limitation in daily activities like reading, watching TV or driving a car).
New Hope for Parkinson’s Patients: Vitamin K2
Vitamin K2 plays a role in the energy production of defective mitochondria and that it potentially offers hope for a new treatment for Parkinson’s.
Researchers have very recently came up with VITAMIN K2, which can cease the progression of Parkinson’s' disease. Parkinsonism is a slowly progressive neurological disorder characterized by progressive dementia with several known etiologies. It is also postulated that disruption of energy production in mitochondria can also be a causative factor. This energy is generated by transferring of electrons. In Parkinson patients, the transportation of electron and mitochondrial activity is disrupted resulting in insufficient production of energy for the cell. This leads to the death of cells in certain parts of brain disrupting communication between neurons. The consequences are the typical symptoms’ of Parkinson’s: Muscle stiffness, tremors and lack of movement (akinesia).
Although the exact root of Parkinson’s diseases is unknown, scientists are successful in unfolding several genetic defects (mutations) found in Parkinson’s patients, including PINK1 and Parkin mutations, both of which lead to reduced mitochondrial activity. By studying these mutations, scientists hope to untangle the mechanisms underlying the disease process.
Experimental Drug May Cut Severe Asthma Attacks: Study
Aug. 16, 2012 -- An experimental drug known as Mepolizumab may reduce outbreaks by almost 50 percent in people with a type of hard-to-treat asthma, an early study finds. The researchers explained that about a third of people with severe asthma have eosinophilic asthma, in which eosinophils cause swelling of lung airways. Standard asthma treatment with inhaled steroids isn't effective, so these patients take oral steroids, which have many side effects. Mepolizumab blocks the production of eosinophils and reduces the frequency of severe asthma outbreaks, which may reduce the need for steroids.
Tofacitinib Appears Effective, Safe for Ulcerative Colitis: Study
Aug. 15, 2012 -- An experimental drug called Tofacitinib reduces the symptoms of ulcerative colitis, at least in the short term. The drug appears relatively safe, with few serious side effects, a new study found. More than three-quarters of those taking the highest dose of the drug -- which is given as a pill -- had a response to the medication, and 41 percent of these patients achieved a remission, according to the study.
Drug safety communication
§  FDA Safety Changes: Statin Label Revised With New Warning

The US Food and Drug Administration (FDA) has approved class safety labeling changes for statins, including removal of the recommendation for routine monitoring of liver enzymes and the addition of new information about reversible cognitive adverse effects and reports of increased blood glucose and glycosylated hemoglobin (HbA1c) levels.

·            FDA: Do Not Prescribe Sildenafil Off-label to Kids With PAH
August 31, 2012 - Clinicians should not prescribe sildenafil on an off-label basis for children to treat pulmonary arterial hypertension (PAH) because low doses do not effectively improve exercise ability, and high doses increase the risk for death, the US Food and Drug Administration (FDA) warned.

FDA Issues New Safety Alert on Reumofan Plus and Reumofan Plus Premium



August 21, 2012 -- The U.S. Food and Drug Administration today issued a new warning to consumers about the potential health risks of two products marketed as natural dietary supplements for treating arthritis, muscle pain, osteoporosis, bone cancer, and other conditions. The products, Reumofan Plus and Reumofan Plus Premium, contain several potentially harmful active pharmaceutical ingredients that are not listed on the product labels.
The FDA has received dozens of additional adverse event reports, including death and stroke, associated with the use of Reumofan Plus since the agency issued its first warning about the product on June 1, 2012. Other reports include liver injury, severe bleeding, sudden worsening of glucose (sugar) control, weight gain, swelling, leg cramps and withdrawal syndrome, and adrenal suppression.
·         Codeine use in certain children after tonsillectomy and/or adenoidectomy may lead to rare, but life-threatening adverse events or death

Aug 15, 2012 - The U.S. Food and Drug Administration (FDA) is reviewing reports of children who developed serious adverse effects or died after taking codeine for pain relief after tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Recently, three pediatric deaths and one non-fatal but life-threatening case of respiratory depression were documented in the medical literature.These children (ages two to five) had evidence of an inherited (genetic) ability to convert codeine into life-threatening or fatal amounts of morphine in the body. All children had received doses of codeine that were within the typical dose range. 
FDA is currently conducting a safety review of codeine to determine if there are additional cases of inadvertent overdose or death in children taking codeine, and if these adverse events occur during treatment of other kinds of pain, such as post-operative pain following other types of surgery or procedures.
Two Antibiotics Linked to Liver Injury in Elderly
Aug. 13, 2012 -- A new study finds that two antibiotics commonly used to treat respiratory and sinus infections -- moxifloxacin and levofloxacin -- may boost the risk of severe liver injury in seniors.
·         Seizure risk for multiple sclerosis patients who take Dalfampridine.
July 23, 2012The U.S. Food and Drug Administration (FDA) is updating health care professionals and the public about the risk of seizures in patients with multiple sclerosis (MS) who are starting dalfampridine.  Using information received from post-market adverse event reports, FDA recently evaluated seizure risk in MS patients taking dalfampridine.  The majority of seizures happened within days to weeks after starting the recommended dose and occurred in patients having no history of seizures.
·         New information regarding QT prolongation with ondansetron (Zofran)
June 29, 2012The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and the public that preliminary results from a recently completed clinical study suggest that a 32 mg single intravenous dose of ondansetron may affect the electrical activity of the heart (QT interval prolongation), which could pre-dispose patients to develop an abnormal and potentially fatal heart rhythm known as Torsades de Pointes.
·         Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment
June 26, 2012 - The U.S. Food and Drug Administration (FDA) is reminding health care professionals about the need to adjust the dosage of the antibacterial drug cefepime in patients with renal (kidney) impairment. There have been cases of a specific type of seizure called nonconvulsive status epilepticus associated with the use of cefepime, primarily in patients with renal impairment who did not receive appropriate dosage adjustments of cefepime.
Cases of nonconvulsive status epilepticus associated with cefepime are documented in the medical literature and have been identified in FDA’s Adverse Event Reporting System (AERS) database .Most cases occurred in patients with renal impairment who did not receive appropriate dosage adjustment.

·         Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Fingolimod

May 14, 2012 - The U.S. Food and Drug Administration (FDA) has completed its evaluation of a report of a patient who died after the first dose of multiple sclerosis drug Fingolimod.  The agency also has evaluated additional clinical trial and postmarket data for fingolimod, including reports of patients who died of cardiovascular events or unknown causes. However, based on its reevaluation of the data, FDA remains concerned about the cardiovascular effects of fingolimod after the first dose. Data show that, although the maximum heart rate lowering effect of fingolimod usually occurs within 6 hours of the first dose, the maximum effect may occur as late as 20 hours after the first dose in some patients.

·         Safety review update of cancer drug Lenalidomide and risk of developing new types of malignancies

May 07, 2012 - The U.S. Food and Drug Administration (FDA) is informing the public of an increased risk of second primary malignancies (new types of cancer) in patients with newly-diagnosed multiple myeloma who received Lenalidomide. Clinical trials conducted after lenalidomide was approved showed that newly-diagnosed patients treated with the drug had an increased risk of developing second primary malignancies compared to similar patients who received a placebo. Specifically, these trials showed there was an increased risk of developing acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma.

·         Updated information on drug interactions between boceprevir and certain boosted HIV protease inhibitor drugs

April 26, 2012 - The U.S. Food and Drug Administration (FDA) is notifying the public that co-administration of boceprevir, a hepatitis C virus (HCV) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended at this time because of the possibility of reducing the effectiveness of the medicines, permitting the amount of HCV or HIV virus in the blood (viral load) to increase. Ritonavir-boosted HIV protease inhibitors include ritonavir-boosted Reyataz (atazanavir), ritonavir-boosted Prezista (darunavir), and Kaletra (lopinavir/ritonavir). 

·         New Warning and Contraindication for blood pressure medicines containing aliskiren
April 20, 2012The U.S. Food and Drug Administration (FDA) is warning of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with diabetes or kidney (renal) impairment.
The following recommendations are being added to the drug labels for aliskiren-containing products as of 4/20/12:
A new contraindication against the use of aliskiren with ARBs or ACEIs in patients with diabetes because of the risk of renal impairment, hypotension, and hyperkalemia.
A warning to avoid use of aliskiren with ARBs or ACEIs in patients with moderate to severe renal impairment (i.e., where glomerular filtration rate [GFR] < 60 mL/min). 

§  Updated information about the risk of blood clots in women taking birth control pills containing drospirenone
April 10, 2012 - The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred to as a progestin.  Based on this review, FDA has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills. FDA is adding information about the studies to the labels of drospirenone-containing birth control pills. 
·         Revised recommendations for citalopram hydrobromide related to a potential risk of abnormal heart rhythms with high doses
March 28, 2012The U.S. Food and Drug Administration (FDA) is clarifying dosing and warning recommendations for the antidepressant citalopram hydrobromide; also available in generic form).  In August 2011, FDA issued a Drug Safety Communication (DSC) stating that citalopram should no longer be used at doses greater than 40 mg per day because it could cause potentially dangerous abnormalities in the electrical activity of the heart. . 
·         Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury
March 01, 2012 - The U.S. Food and Drug Administration (FDA) is issuing updated recommendations concerning drug-drug interactions between drugs for human immunodeficiency virus (HIV) or hepatitis C virus (HCV) known as protease inhibitors and certain cholesterol-lowering drugs known as statins. Protease inhibitors and statins taken together may raise the blood levels of statins and increase the risk for muscle injury (myopathy). The most serious form of myopathy, called rhabdomyolysis, can damage the kidneys and lead to kidney failure, which can be fatal.
·         Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs)
Feb 08, 2012The U.S. Food and Drug Administration (FDA) is informing the public that the use of stomach acid drugs known as proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile–associated diarrhea (CDAD). A diagnosis of CDAD should be considered for patients taking PPIs who develop diarrhea that does not improve.
·         Brentuximab vedotin: Progressive Multifocal Leukoencephalopathy and Pulmonary Toxicity
FDA notified healthcare professionals that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, have been reported with the lymphoma drug brentuximab vedotin. Due to the serious nature of PML, a new Boxed Warning highlighting this risk has been added to the drug label. In addition, a new Contraindication warning was added against use of the drug with the cancer drug bleomycin due to increased risk of pulmonary (lung) toxicity.

·         CardioGen-82 PET Scan: Drug Safety Communication - Increased Radiation Exposure

01/12/2012 - FDA is updating healthcare professionals and the public about preliminary findings from ongoing investigations following the voluntary recall of CardioGen-82 by the manufacturer. FDA continues to work with the manufacturer and other federal agencies to better characterize the problems that led to excessive radiation exposure to patients at certain clinical sites, and is working with the manufacturer to revise the CardioGen-82 labeling to better describe how to use the generator.

FDA ALERTS
Pfizer Removes Breast, Colon Cancer Claims from Vitamins
 Pfizer is removing claims for "breast health" and "colon health" from labeling on its popular Centrum vitamins line of products, after being accused of deceptive advertising that mislead consumers into thinking that these pills will help ward off cancer. Pfizer will alter label wording to resolve the issue.
FDA Issues New Safety Alert on Reumofan Plus and Reumofan Plus Premium



August 21, 2012 -- The U.S. Food and Drug Administration today issued a new warning to consumers about the potential health risks of two products marketed as natural dietary supplements for treating arthritis, muscle pain, osteoporosis, bone cancer, and other conditions. The products, Reumofan Plus and Reumofan Plus Premium, contain several potentially harmful active pharmaceutical ingredients that are not listed on the product labels.

DRUG RECALLS
Ø  Acetylcysteine Solution, USP (Roxane Laboratories, Inc.): - Visible Glass Particle
Ø  Leucovorin calcium injection (Bedford laboratories):-Visible Particulate Matter
Ø  Vecuronium Bromide For Injection Preservative free (Bedford laboratories):-Visible Particulate Matter
GENERAL TOPIC
        Hepatitis A Vaccine for Children Lasts for 10 Years: Study
Aug. 14, 2012 -- Children younger than 2 years who are given the hepatitis A vaccine are protected from the virus for 10 years, a new study shows.
Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
Aug. 14, 2012 -- The relatively new drug Denosumab reduces bone complications of advanced breast cancer more effectively than another osteoporosis drug, zoledronic acid, according to new research. Zoledronic acid belongs to a class of drugs known as bisphosphonates, which help delay bone complications such as fractures, spinal cord compression and bone pain. But it has been linked with kidney toxicity and other reactions. The study found that Denosumab, a newer drug called a monoclonal antibody, is superior to zoledronic acid in reducing skeletal problems and better tolerated.
Vandetanib May Aid People with Advanced Thyroid Cancer
Aug. 13, 2012 -- A new study shows that the chemotherapy drug Vandetanib may extend life a bit for some thyroid cancer patients. The results of phase 2 trials showed that patients taking the drug lived for 11 months without the cancer progressing, compared with six months for those receiving a placebo.
Antibiotic Use in Infants Tied to Overweight Later: Study
Aug. 21, 2012 -- Infants who receive antibiotics before they're 6 months old may have a higher risk of being overweight later in childhood, a new study finds.
Ø  Newer Psoriasis Drugs May Lower Heart Attack Risk for Patients
Aug. 20, 2012 -- People with psoriasis who take a new class of drugs known as tumor necrosis factor (TNF) inhibitors may be at a lower risk for heart attack than their counterparts who only use topical medications to treat this inflammatory skin condition, a new study shows.
And patients taking older systemic medicines and phototherapy may also have a reduced heart attack risk compared to those using topical preparations, the study found.
Vitamin D May Thwart Kids' Winter Colds
Aug. 23, 2012 -- Taking vitamin D supplements may lower children's risk of respiratory infections, according to a new study. The study included nearly 250 schoolchildren in Mongolia with low blood levels of vitamin D during winter. Taking a daily vitamin D supplement reduced their risk of respiratory infection by half, the researchers said.

No comments:

Post a Comment